Skip to main content
. 2021 Feb 14;13(4):799. doi: 10.3390/cancers13040799

Figure 2.

Figure 2

Targeting metabolic reprogramming in patients with PCa. KRAS-mutant tumors rely on metabolic reprogramming, exposing critical vulnerabilities to target for therapy. MCT1/2, monocarboxylate transporters 1/2; ACSL3, acyl-CoA synthetase long-chain 3.